About this trial

Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\<2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.

Eligibility criteria

Qualifiers

Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;

Diagnosis of non-severe (qSOFA < 2) urinary tract infection coupled with fever ≥ 38°C or < 36°C

Presence of bacteria in the fresh urine sample and/or GNB on the Gram stain

Empirical parenteral antibiotic therapy required; Hospitalization required;

Disqualifiers

Pregnant and/or breastfeeding

Neutropenia (absolute neutrophil count < 500 / mm3)

Severe UTI with sepsis (qSOFA ≥ 2) or septic shock

Urinary derivation required (ureteral catheter/per-cutaneous nephrostomy) except for simple urinary catheterization

Trial design

Treatments tested in this trial

  • Detection of integrons
  • Gold standard

Treatment groups

204 Participants
are divided into 2 treatment groups

Locations

7
CHRU Tours, Hôpital Trousseau37170, Chambray-lès-Tours France
Grenoble university hospital38700, La Tronche France
Limoges university hospital87042, Limoges France
Groupe Hospitalier Universitaire Bichat-Claude Bernard - APHP75018, Paris France

Sponsors and collaborators

University Hospital, Limoges

Lead sponsor